- The Minister for Finance, Mr. Brian Lenihan T.D.
today performed the official opening of the centre which will play a
significant role in Helsinn group's pipeline of new products.
The Swiss pharmaceutical group Helsinn announced the official
opening, performed today by the Minister for Finance, Mr. Brian
Lenihan T.D, of its new R&D Centre of Excellence in Mulhuddart, Co.
Dublin. The centre, which will play a significant role in Helsinn
Group's pipeline of new products including the NK-1 inhibitor
Netupitant for the treatment of emesis due to chemotherapy, and the
novel ghrelin analogue Anamorelin for the treatment of cachexia,
involved an investment of Euro 13 million, supported by the Irish
Government through IDA Ireland. The investment is expected to create
up to 10 high-value research positions over the next few years.
Helsinn announced its plans to establish the facility in April
2009, and following a successful construction phase the plant is now
ready to commence operations. The centre will be responsible for
Research & Development for Oral Solid Dosage (OSD) at the company's
Helsinn Birex Pharmaceuticals facility at Mulhuddart, Dublin, which
currently produces a range of drug products.
The investment is part of Helsinn's strategic decision to
strengthen its in-house development capability enabling better
control of cost and time in bringing new therapies to patients
During the official opening Mr. Riccardo Braglia, Chief Executive
Officer of the Helsinn Group said, "Helsinn is pleased to confirm the
completion of this investment in our R&D Centre on time and in budget
which will be of significant benefit for the future of our
international business, by centralising the development and
commercialisation of Oral Solid Dosage products for better management
of our resources and flexibility to better serve our partners
Helsinn's Irish operation was established in 1990, when it
acquired Birex Pharmaceuticals in Dublin. To-date Helsinn has
invested a total of over Euro 60 million in Ireland and continuously
invests in its plants in order to maintain high quality and safety,
to increase overall production capacity and to offer its partners
up-to-date products, technologies and services. It now employs a
total of 145 people at its Helsinn Birex Pharmaceuticals facility
from which it supplies global markets with a range of products
including its highly successful product Palonosetron which is
effective for treatment of chemotherapy-induced nausea and vomiting,
as well as Nimesulide (anti-inflammatory) and Klean-Prep®
The Minister for Finance, Mr. Brian Lenihan said, "I am delighted
to officially open Helsinn's Centre of Excellence in Dublin today.
This investment is highly significant for Ireland as it places
Helsinn's Irish operation at the centre of Helsinn Group's worldwide
R&D operations. The Irish Centre of Knowledge and Learning for OSD
products will play a pivotal role in facilitating the growth of
Helsinn's worldwide business by acting as a launch site for new
products within its portfolio. This investment is a further
endorsement of Ireland as a prime location for highly innovative
companies carrying out key strategic activities".
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with
headquarters in Lugano, Switzerland and subsidiaries in Ireland and
USA. Helsinn's unique business model is focused on the licensing of
pharmaceuticals and medical devices in therapeutic niche areas. The
Group in-licenses early to late stage new chemical entities,
completes their development from the performance of pre-
clinical/clinical studies and Chemistry, Manufacturing and Control
(CMC) development, to the filing for and attainment of their market
Helsinn's products are sold directly, through the Group
subsidiaries, or alternatively out-licensed to its network of local
marketing and commercial partners, selected for their deep in-market
knowledge and know-how, and assisted and supported with a full range
of product and scientific management services, including commercial,
regulatory, financial, legal and medical marketing advice. The active
pharmaceutical ingredients and the finished dosage forms are
manufactured at Helsinn's cGMP facilities in Switzerland and Ireland,
and supplied worldwide to its customers.
Helsinn is the worldwide licensor of palonosetron, a second
generation 5-HT3 receptor antagonist, for the prevention of
chemotherapy-induced nausea and vomiting (CINV) in patients with
cancer and of post-operative nausea and vomiting (PONV), and of the
original nimesulide, a non-steroidal anti-inflammatory drug (NSAID)
distributed in more than 50 countries worldwide. Helsinn, with a
workforce of around 450 employees in Switzerland, Ireland and USA,
reported a 2009 turnover of over CHF 305.0 million (about EUR 232.0
million at the current conversion exchange rate), covering 85
countries worldwide, with over 20% of this turnover invested in R&D.
For more information on the Helsinn Group please visit the
About Helsinn in Ireland
Helsinn has operated in Ireland since 1990 and its Irish
manufacturing facilities are EU certified for manufacture of
pharmaceutical products and were successfully inspected by the US
Food and Drug Administration earlier this year. The company
manufactures and packages the group's products in compliance with EU,
US FDA and all major international health and environmental
requirements, thus guaranteeing Helsinn's clients the highest
possible assurance of quality and reliability.
ots Originaltext: Helsinn Healthcare SA
Helsinn Birex Pharmaceuticals Ltd.
Padraig Somers, General Manager